- Home
- CINT vs MRVI Comparison
CINT vs MRVI Comparison
Compare CINT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CINT | MRVI |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.6M | 472.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CINT | MRVI |
|---|---|---|
| Price | $4.99 | $3.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $7.00 | $4.57 |
| AVG Volume (30 Days) | 195.7K | ★ 1.1M |
| Earning Date | 03-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.10 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $467,906,000.00 | $192,435,000.00 |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $12.62 | $10.00 |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | ★ 1.90 | N/A |
| 52 Week Low | $3.98 | $1.67 |
| 52 Week High | $8.00 | $5.03 |
Technical Indicators
Market Signals| Indicator | CINT | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 35.06 |
| Support Level | $4.83 | $3.07 |
| Resistance Level | $5.35 | $3.51 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 53.19 | 6.06 |
Price Performance
Historical ComparisonAbout CINT CI&T Inc
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.